By PPN News Staff
The FDA approved obiltoxaximab (Anthim, Elusys Therapeutics) injection to treat inhalation anthrax in combination with appropriate antibacterial drugs. Obiltoxaximab also is approved to prevent inhalation anthrax when alternative therapies are not available or not appropriate.
Inhalation anthrax is a rare disease that can occur after exposure to infected animals or contaminated animal products, or as a result of an intentional release of anthrax spores. It is caused